Literature DB >> 16406907

Is the bladder a reliable witness for predicting detrusor overactivity?

H Hashim1, P Abrams.   

Abstract

PURPOSE: We determined how well the symptoms of OAB syndrome correlate with urodynamic DO using International Continence Society definitions.
MATERIALS AND METHODS: The study included adult males and females 18 years or older who attended a tertiary referral center for urodynamics from February 2002 to February 2004. Patients were selected based on OAB syndrome symptoms (urgency, urgency urinary incontinence and frequency). The percent of patients who had symptoms alone or in combination and DO was calculated.
RESULTS: There was a better correlation in results between OAB symptoms and the urodynamic diagnosis of DO in men than in women. Of men 69% and 44% of women with urgency (OAB dry) had DO, while 90% of men and 58% of women with urgency and urgency urinary incontinence (OAB wet) had DO. Stress urinary incontinence seems to have accounted for the decreased rates in women since 87% of women with urgency urinary incontinence also had the symptom of stress urinary incontinence. The ICS definition does not specify what constitutes abnormal voiding frequency. Analysis of results showed that increasing voiding frequency did not have any effect on increasing the accuracy of diagnosis of DO except in women with 10 or more daytime micturition episodes.
CONCLUSIONS: The bladder is a better and more reliable witness in men than in women with a greater correlation between OAB symptoms and urodynamic DO, more so in the OAB wet than in OAB dry patients.

Entities:  

Mesh:

Year:  2006        PMID: 16406907     DOI: 10.1016/S0022-5347(05)00067-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  61 in total

Review 1.  Pharmacological management of women with mixed urinary incontinence.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.

Authors:  Seyfettin Ciftci; Cuneyd Ozkurkcugil; Hasan Yilmaz; Murat Ustuner; Ufuk Yavuz; Mustafa Yuksekkaya; Mustafa Baki Cekmen
Journal:  Int Urogynecol J       Date:  2015-08-27       Impact factor: 2.894

3.  Persistent detrusor overactivity after transurethral resection of the prostate.

Authors:  Fadi Housami; Paul Abrams
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

4.  Assessment of bladder wall thickness in women with overactive bladder.

Authors:  Oktay Üçer; Bilal Gümüş; Ali Can Albaz; Gökhan Pekindil
Journal:  Turk J Urol       Date:  2016-06

5.  The overactive bladder.

Authors:  Richard Foon; Marcus J Drake
Journal:  Ther Adv Urol       Date:  2010-08

6.  Lower urinary tract symptoms in women with benign joint hypermobility syndrome: a case-control study.

Authors:  H Mastoroudes; I Giarenis; L Cardozo; S Srikrishna; M Vella; D Robinson; H Kazkaz; R Grahame
Journal:  Int Urogynecol J       Date:  2013-02-23       Impact factor: 2.894

7.  What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence--a multi-centre randomised controlled trial.

Authors:  Robert Freeman; David Holmes; Timothy Hillard; Phillip Smith; Mark James; Abdul Sultan; Roland Morley; Qian Yang; Paul Abrams
Journal:  Int Urogynecol J       Date:  2011-01-11       Impact factor: 2.894

8.  Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity.

Authors:  Michael L Guralnick; Gwen Grimsby; Michael Liss; Aniko Szabo; R Corey O'Connor
Journal:  Int Urogynecol J       Date:  2009-11-12       Impact factor: 2.894

Review 9.  How do urodynamics findings influence the treatment of the typical patient with overactive bladder?

Authors:  Matthew P Rutman; Doh Yoon Cha; Jerry G Blaivas
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

Review 10.  Basic mechanisms of urgency: roles and benefits of pharmacotherapy.

Authors:  Martin Christian Michel; Christopher R Chapple
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.